ATE324873T1 - Zellulosederivatkapsel, wie z. b. hpmc, die benzimidazolderivat enthaelt, wie z.b. omeprazol - Google Patents

Zellulosederivatkapsel, wie z. b. hpmc, die benzimidazolderivat enthaelt, wie z.b. omeprazol

Info

Publication number
ATE324873T1
ATE324873T1 AT01983069T AT01983069T ATE324873T1 AT E324873 T1 ATE324873 T1 AT E324873T1 AT 01983069 T AT01983069 T AT 01983069T AT 01983069 T AT01983069 T AT 01983069T AT E324873 T1 ATE324873 T1 AT E324873T1
Authority
AT
Austria
Prior art keywords
derivative
capsule
omeprazole
hpmc
cellulose
Prior art date
Application number
AT01983069T
Other languages
English (en)
Inventor
Judita Sirca
Original Assignee
Lek Farmacevtska Druzba Dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324873(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Farmacevtska Druzba Dd filed Critical Lek Farmacevtska Druzba Dd
Application granted granted Critical
Publication of ATE324873T1 publication Critical patent/ATE324873T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01983069T 2000-11-20 2001-11-20 Zellulosederivatkapsel, wie z. b. hpmc, die benzimidazolderivat enthaelt, wie z.b. omeprazol ATE324873T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200000282A SI20720A (sl) 2000-11-20 2000-11-20 Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola

Publications (1)

Publication Number Publication Date
ATE324873T1 true ATE324873T1 (de) 2006-06-15

Family

ID=20432767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983069T ATE324873T1 (de) 2000-11-20 2001-11-20 Zellulosederivatkapsel, wie z. b. hpmc, die benzimidazolderivat enthaelt, wie z.b. omeprazol

Country Status (9)

Country Link
US (2) US20040029924A1 (de)
EP (1) EP1335709B1 (de)
AT (1) ATE324873T1 (de)
AU (2) AU2002214524B2 (de)
DE (1) DE60119367T2 (de)
ES (1) ES2263675T3 (de)
PL (1) PL360972A1 (de)
SI (1) SI20720A (de)
WO (1) WO2002039980A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
AU2003272081A1 (en) * 2003-09-25 2005-04-11 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
JPWO2005084649A1 (ja) * 2004-03-04 2007-11-29 武田薬品工業株式会社 安定なカプセル剤
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
WO2008018825A1 (en) * 2006-08-10 2008-02-14 Astrazeneca Ab Oral polyvinyl alcohol capsules comprising proton pump inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5264223A (en) * 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) * 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
EP1072258A1 (de) * 1999-07-28 2001-01-31 Greither, Peter Eine Kapsel für die Freisetzung von Bakterien, enthaltend ein Bakterienlyophilisat und ein Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
EP1335709A2 (de) 2003-08-20
AU1452402A (en) 2002-05-27
AU2002214524B2 (en) 2007-03-01
WO2002039980A2 (en) 2002-05-23
WO2002039980A3 (en) 2002-07-11
SI20720A (sl) 2002-06-30
US20040029924A1 (en) 2004-02-12
US20090226511A1 (en) 2009-09-10
ES2263675T3 (es) 2006-12-16
PL360972A1 (en) 2004-09-20
DE60119367T2 (de) 2007-04-19
EP1335709B1 (de) 2006-05-03
DE60119367D1 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
NO20023313D0 (no) Nye substituerte benzimidazol doseringsformer og fremgangsmåte for anvendelse av samme
AR016827A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AP1954A (en) Controlled release compositions comprising nimesulide.
NO20043723L (no) Farmasoytisk doseringform for avgivese gjennom slimhinner
IL116084A0 (en) Pharmaceutical compositions containing ondansetron and their use
NO20022058D0 (no) Farmasöytiske sammensetninger
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
IL143375A0 (en) Sustained release matrix systems for highly soluble drugs
ATE292453T1 (de) Antivirale arznei
ATE324873T1 (de) Zellulosederivatkapsel, wie z. b. hpmc, die benzimidazolderivat enthaelt, wie z.b. omeprazol
AP2003002763A0 (en) Controlled release formulations for oral administration
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
SE9003904D0 (sv) Method for the manufacture of a pharmaceutical dosage form
NO20013205L (no) Farmasöytiske formuleringer i hydroksypropylmetylcellulosekapsler
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
YU47044B (sh) Postupak za dobijanje tableta sa produženim delovanjem na bazi hidroksipropil-metilceluloze velike molekularne mase
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
TW200517127A (en) Novel composition
ATE266404T1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
AR018041A1 (es) Formulaciones de tiagabina de liberacion prolongada, encapsulada y en comprimidos
FR2797446B1 (fr) Derives de phenanthroline-7-ones et leurs applications en therapeutique
MY145885A (en) Controlled release formulations for oral administration

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1335709

Country of ref document: EP